MOTS-c is an unregulated research compound, FDA-ineligible for compounding, and prohibited by WADA under S4.4.1 (AMPK activators)
Daily doses for extended periods (months to years) push into territory where chronic effects could emerge without warning
(NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, reported completion of the safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC combination in Alzheimer's disease
My loading doses have been every 2 weeks for 2 months (my final will be next weekend), then monthly
In a small study of 10 children aged 3 to 16, DSIP treatment improved abnormal brain electrical activity patterns in 9 out of 10 patients, demonstrating potential neuroprotective properties beyond sleep regulation